« Top Headlines » Open DEMAT Account in 24 hrs  Delhi HC Rules GST Registration Cannot Be Cancelled Retrospectively Without a Clear Show Cause Notice (SCN)  Belated income tax return AY 2026-27: How to file, late filing charges and what you may lose  Major Financial Changes from August 1, 2026: ITR Deadline, RBI MPC Meeting, Tatkal Ticket Rules & More  Government proposes to ease tax relief conditions for offshore funds  TallyPrime Connected Banking: Automating Banking and Accounting  ITR Filing Deadline 2026: Is July 31 the Last Date to File Your Income Tax Return? Latest Official Update  ITR filing deadline nears: How to file income tax return online on e-filing portal - quick 15-step guide  Will the ITR Filing Deadline Be Extended Beyond July 31 for FY 2025-26? Here's the Latest Update for Taxpayers  Income Tax Refund Delayed for AY 2026-27? 5 Common Reasons Your Refund May Be Stuck and How to Fix It  ITR Filing 2026: FM Nirmala Sitharaman Asks Tax Officials to Let Honest Taxpayers Correct Genuine Mistakes  Will Your FCNR Deposit Stay Tax-Free After Returning to India? Tax Rules Explained for NRIs «  Telecom industry for tax holiday... HC notice to finmin over non-CA tax preparers... » Cabinet to look into amendment November, 21st 2006 In a move that will boost the pharmaceutical sector, the Cabinet Committee on World Trade Organisation is expected to take up a proposal for amending the compulsory license clause in the Trade-Related Intellectual Property Rights (TRIPS) agreement.    Once this decision is taken, the Centre will propose to WTO to waive off the obligation under Article 31(f) and Article 31(h) of the TRIPS agreement, so that it can directly export pharma products to countries having insufficient or no manufacturing capacity.    Under the current circumstances, a government has an exceptional provision of allowing a pharma company to produce the patented product or process without the consent of the patent owner in case of a medical emergency.    But if the article is relaxed for India, domestic companies will be able to export the products to other countries in case of national emergencies without the authorisation of the patent holder.    Article 31(h) of TRIPS specifies that the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorisation benefit.